Racetam
Coluracetam
SaveA racetam that enhances high-affinity choline uptake (HACU) in hippocampal neurons. Originally developed by Mitsubishi Tanabe Pharma for Alzheimer's disease.
Quick verdict
Novel HACU mechanism is pharmacologically interesting but clinical development was abandoned after underwhelming Phase II depression/anxiety results.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Phase IIa trials for major depression and generalized anxiety by BrainCells Inc. showed mixed results, and development was not continued. Rodent data demonstrates HACU enhancement and pro-cognitive effects even after washout, suggesting lasting cholinergic plasticity.
Benefits
- Unique HACU enhancement mechanism
- Sustained pro-cognitive effect in rats even after washout
- Anecdotal reports of enhanced color perception and visual clarity
Dosage notes
Phase II used 80 mg three times daily. Nootropic users typically report 20–80 mg/day.
Side effects
- Headache
- Fatigue
- Anxiety at higher doses
Who should be cautious
Investigational compound with incomplete safety profiling. Not approved anywhere.
What this page cannot tell you
Abandoned by its developer after unconvincing Phase II results. Remaining interest is primarily in the nootropic community.
Leaderboard scores
- Memory30
- Focus30
- Mood25
Write a review
Sign in to write a review.